Signal from the log
EIT Pharma
35 M$ · Series A · United States · Biotech
EIT Pharma porte le lonafarnib, un antiviral oral contre l'hépatite delta chronique, dont elle a racheté l'actif en septembre 2024 à Eiger BioPharmaceuticals en faillite. Elle a annoncé le 11 août 2026 que la FDA avait accepté son dossier d'enregistrement.
Verified
Announced on , logged by the watch of 31 August 2026.
- Operation
- Funding round
- Announced amount
- 35 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Propel Bio Partners , with Good Ventures , Arrowtown
Provenance
Source prnewswire
Logged on 31 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.